サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1276932

膵外分泌機能不全（EPI）治療および診断の世界市場

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
出版日: | 発行: Data Bridge Market Research | ページ情報: 英文 160 Pages | 納期: お問合せ

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.65円
膵外分泌機能不全（EPI）治療および診断の世界市場
出版日: 2023年04月01日
発行: Data Bridge Market Research
ページ情報: 英文 160 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の膵外分泌機能不全（EPI）治療および診断の市場規模は、2023年～2030年の予測期間中に7.2%のCAGRで拡大し、2022年の76億7,500万米ドルから2030年には133億8,556万米ドルに達すると予測されています。

当レポートでは、世界の膵外分泌機能不全（EPI）治療および診断市場について調査し、市場の概要とともに、治療別、診断別、薬剤タイプ別、エンドユーザー別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 業界考察

第6章 規制の枠組み

第7章 市場概要

  • 促進要因
  • 抑制要因
  • 機会
  • 課題

第8章 世界の膵外分泌機能不全（EPI）治療および診断市場、治療別

  • 概要
  • 膵臓酵素補充療法（PERT）
  • 栄養管理

第9章 世界の膵外分泌機能不全（EPI）治療および診断市場、診断別

  • 概要
  • 膵臓機能検査
  • 画像検査

第10章 世界の膵外分泌機能不全（EPI）治療および診断市場、薬剤タイプ別

  • 概要
  • ブランド薬
  • ジェネリック薬

第11章 世界の膵外分泌機能不全（EPI）治療および診断市場、エンドユーザー別

  • 概要
  • 病院
  • 専門クリニック
  • 診断センター
  • 在宅ケア
  • 学術・研究機関
  • その他

第12章 世界の膵外分泌機能不全（EPI）治療薬および診断薬市場、流通チャネル別

  • 概要
  • 直接入札
  • 小売薬局
  • サードパーティの販売代理店
  • その他

第13章 世界の膵外分泌機能不全（EPI）治療および診断市場、地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第14章 世界の膵外分泌機能不全（EPI）治療および診断市場：企業情勢

第15章 SWOT分析

第16章 企業プロファイル

  • ABBVIE INC.
  • ABBOTT
  • NESTLE
  • LABORATORY CORPORATION OF AMERICA HOLDINGS
  • JANSSEN GLOBAL SERVICES, LLC
  • ALCRESTA THERAPEUTICS, INC.
  • BIOSERV DIAGNOSTICS GMBH
  • CILIAN AG
  • CHIRHOCLIN
  • DIGESTIVE CARE, INC.
  • EAGLEBIO
  • METAGENICS LLC
  • NORDMARK
  • ORGANON GROUP OF COMPANIES.
  • SCHEBO BIOTECH AG
  • VIVUS LLC

第17章 アンケート

第18章 関連レポート

図表

LIST OF TABLES

  • TABLE 1 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT, 2021-2030 (USD MILLION) 56
  • TABLE 2 GLOBAL PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 56
  • TABLE 3 GLOBAL PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ENZYME, 2021-2030 (USD MILLION) 57
  • TABLE 4 GLOBAL PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 57
  • TABLE 5 GLOBAL ORAL IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 58
  • TABLE 6 GLOBAL NUTRITIONAL MANAGEMENT IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 59
  • TABLE 7 GLOBAL NUTRITIONAL MANAGEMENT IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT, 2021-2030 (USD MILLION) 60
  • TABLE 8 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION) 64
  • TABLE 9 GLOBAL PANCREATIC FUNCTION TEST IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 65
  • TABLE 10 GLOBAL PANCREATIC FUNCTION TEST IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION) 65
  • TABLE 11 GLOBAL STOOL IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION) 65
  • TABLE 12 GLOBAL IMAGING TESTS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 67
  • TABLE 13 GLOBAL IMAGING TESTS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION) 67
  • TABLE 14 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 72
  • TABLE 15 GLOBAL BRANDED IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 73
  • TABLE 16 GLOBAL BRANDED IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION) 73
  • TABLE 17 GLOBAL GENERIC IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
  • TABLE 18 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 79
  • TABLE 19 GLOBAL HOSPITALS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
  • TABLE 20 GLOBAL HOSPITALS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 80
  • TABLE 21 GLOBAL SPECIALTY CLINICS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
  • TABLE 22 GLOBAL DIAGNOSTIC CENTER IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 23 GLOBAL HOMECARE IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 24 GLOBAL RESRACH AND ACADEMIC INSTITUTES IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
  • TABLE 25 GLOBAL OTHERS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
  • TABLE 26 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 88
  • TABLE 27 GLOBAL DIRECT TENDER IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
  • TABLE 28 GLOBAL RETAIL PHARMACY IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
  • TABLE 29 GLOBAL THIRD PARTY DISTRIBUTORS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
  • TABLE 30 GLOBAL OTHERS IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91

LIST OF FIGURES

  • FIGURE 1 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SEGMENTATION 21
  • FIGURE 2 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: DATA TRIANGULATION 24
  • FIGURE 3 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: DROC ANALYSIS 25
  • FIGURE 4 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 26
  • FIGURE 5 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 26
  • FIGURE 6 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 28
  • FIGURE 7 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 29
  • FIGURE 8 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: MARKET TESTING TYPE COVERAGE GRID 30
  • FIGURE 9 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 31
  • FIGURE 10 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SEGMENTATION 34
  • FIGURE 11 INCREASING PREVALENCE OF EXOCRINE PANCREATIC INSUFFICIENCY (EPI) DUE TO CHRONIC PANCREATITIS AND CYSTIC FIBROSIS IS EXPECTED TO DRIVE THE FIGURE 10 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET IN THE FORECAST PERIOD 35
  • FIGURE 12 THE PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET IN 2023 & 2030 35
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 36
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD 37
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET 45
  • FIGURE 16 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, 2022 53
  • FIGURE 17 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, 2023-2030 (USD MILLION) 54
  • FIGURE 18 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, CAGR (2023-2030) 54
  • FIGURE 19 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT, LIFELINE CURVE 55
  • FIGURE 20 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, 2022 62
  • FIGURE 21 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, 2023-2030 (USD MILLION) 63
  • FIGURE 22 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, CAGR (2023-2030) 63
  • FIGURE 23 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DIAGNOSIS, LIFELINE CURVE 64
  • FIGURE 24 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, 2022 70
  • FIGURE 25 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION) 71
  • FIGURE 26 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, CAGR (2023-2030) 71
  • FIGURE 27 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DRUG TYPE, LIFELINE CURVE 72
  • FIGURE 28 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, 2022 77
  • FIGURE 29 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 78
  • FIGURE 30 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 78
  • FIGURE 31 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 79
  • FIGURE 32 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 86
  • FIGURE 33 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 87
  • FIGURE 34 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 87
  • FIGURE 35 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 88
  • FIGURE 36 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022) 94
  • FIGURE 37 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY REGION (2022) 95
  • FIGURE 38 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY REGION (2023 & 2030) 95
  • FIGURE 39 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY REGION (2022 & 2030) 96
  • FIGURE 40 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030) 96
  • FIGURE 41 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022) 98
  • FIGURE 42 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022) 99
  • FIGURE 43 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 99
  • FIGURE 44 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 100
  • FIGURE 45 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030) 100
  • FIGURE 46 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022) 103
  • FIGURE 47 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022) 104
  • FIGURE 48 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 104
  • FIGURE 49 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 105
  • FIGURE 50 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030) 106
  • FIGURE 51 ASIA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022) 110
  • FIGURE 52 ASIA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022) 111
  • FIGURE 53 ASIA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 111
  • FIGURE 54 ASIA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 112
  • FIGURE 55 ASIA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030) 112
  • FIGURE 56 SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022) 116
  • FIGURE 57 SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022) 117
  • FIGURE 58 SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 117
  • FIGURE 59 SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 118
  • FIGURE 60 SOUTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030) 118
  • FIGURE 61 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: SNAPSHOT (2022) 121
  • FIGURE 62 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022) 122
  • FIGURE 63 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 122
  • FIGURE 64 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 123
  • FIGURE 65 MIDDLE EAST AND AFRICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: BY TREATMENT (2023-2030) 123
  • FIGURE 66 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 126
  • FIGURE 67 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 127
  • FIGURE 68 EUROPE EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 128
  • FIGURE 69 AISA-PACIFIC EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICSMARKET: COMPANY SHARE 2022 (%) 129
目次

Global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is expected to reach USD 13,385.56 million by 2030 from USD 7,675.00 million in 2022, growing at a CAGR of 7.2% during the forecast period from 2023 to 2030.

Market Segmentation:

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, By Dignosis (Imaging Tests and Pancreatic Function Test), Treatment (Nutritional Management and Pancreatic Enzyme Replacement Therapy (PERT), and Others), Drugs Type (Branded and Generic), End User (Specialty Clinics, Hospitals, Diagnostic Center, Homecare, Research and Academic Institutes, and Others), Distribution Channel (Direct Tender, Retail Pharmacy, Third Party Distributors, and Others), Industry Trends and Forecast to 2030.

Overview of Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Dynamics:

Driver

Increasing prevalence of exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis and cystic fibrosis

Restraint

Stringent regulations to hamper the exocrine pancreatic insufficiency (EPI) therapeutic and diagnostic sector

Opportunity

Increasing prevalence of pancreatic disorders and associated conditions

Market Players:

Some of the key market players operating in the global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are listed below:

EagleBio

AbbVie.

Digestive Care, Inc.

Nordmark Arzneimittel GmbH & Co.

Cilian AG

Alcresta Therapeutics, Inc.

ChiRhoClin

Bioserv Diagnostics

Laboratory Corporation of America

Organon group of companies

Metagenics LLC

Janssen

Nestle.

VIVUS LLC.

ScheBo Biotech AG

Abbott.

TABLE OF CONTENTS

1 INTRODUCTION 16

  • 1.1 OBJECTIVES OF THE STUDY 16
  • 1.2 MARKET DEFINITION 16
  • 1.3 OVERVIEW OF GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET 16
  • 1.4 LIMITATIONS 18
  • 1.5 MARKETS COVERED 18

2 MARKET SEGMENTATION 21

  • 2.1 MARKETS COVERED 21
  • 2.2 GEOGRAPHICAL SCOPE 22
  • 2.3 YEARS CONSIDERED FOR THE STUDY 23
  • 2.4 CURRENCY AND PRICING 23
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 24
  • 2.6 MULTIVARIATE MODELLING 27
  • 2.7 PRODUCT TYPE LIFELINE CURVE 27
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
  • 2.9 DBMR MARKET POSITION GRID 29
  • 2.10 MARKET TESTING TYPE COVERAGE GRID 30
  • 2.11 VENDOR SHARE ANALYSIS 31
  • 2.12 SECONDARY SOURCES 32
  • 2.13 ASSUMPTIONS 32

3 EXECUTIVE SUMMARY 33

4 PREMIUM INSIGHTS 35

  • 4.1 PESTEL ANALYSIS 38
  • 4.2 PORTER ANALYSIS 39

5 INDUSTRY INSIGHTS 40

6 REGULATORY FRAMEWORK 42

7 MARKET OVERVIEW 44

  • 7.1 DRIVERS 46
    • 7.1.1 INCREASING PREVALENCE OF EXOCRINE PANCREATIC INSUFFICIENCY (EPI) DUE TO CHRONIC PANCREATITIS AND CYSTIC FIBROSIS 46
    • 7.1.2 RISING TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSIS AND TREATMENT OF EPI 46
    • 7.1.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 47
    • 7.1.4 SEDENTARY LIFESTYLES AND UNHEALTHY DIETS 47
  • 7.2 RESTRAINTS 48
    • 7.2.1 STRINGENT REGULATIONS TO HAMPER THE EXOCRINE PANCREATIC INSUFFICIENCY(EPI) THERAPEUTIC AND DIAGNOSTIC SECTOR 48
    • 7.2.2 SIDE EFFECTS AND RELIGIOUS HURDLES ASSOCIATED WITH PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) 48
  • 7.3 OPPORTUNITIES 49
    • 7.3.1 INCREASING PREVALENCE OF PANCREATIC DISORDERS AND ASSOCIATED CONDITION 49
    • 7.3.2 RISING AWARENESS ABOUT THE BENEFITS OF EARLY DIAGNOSIS AND TREATMENT OF EPI 49
    • 7.3.3 GROWING DEMAND FOR COMBINATION THERAPIES AND PERSONALIZED MEDICINE 50
  • 7.4 CHALLENGES 51
    • 7.4.1 HIGH COST ASSOCIATED WITH EPI DIAGNOSIS AND TREATMENT 51
    • 7.4.2 LIMITED AVAILABILITY OF EPI THERAPEUTICS AND DIAGNOSTICS 51

8 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT 52

  • 8.1 OVERVIEW 53
  • 8.2 PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) 56
    • 8.2.1 BY ENZYME 56
      • 8.2.1.1 LIPASE 57
      • 8.2.1.2 PROTEASE 57
      • 8.2.1.3 AMYLASE 57
    • 8.2.2 BY ROUTE OF ADMINISTRATION 57
      • 8.2.2.1 ORAL 58
        • 8.2.2.1.1 CAPSULES 58
        • 8.2.2.1.2 TABLETS 58
        • 8.2.2.1.3 POWDER 58
      • 8.2.2.2 INTRAVENOUS 58
  • 8.3 NUTRITIONAL MANAGEMENT 59
    • 8.3.1 VITAMIN D 60
    • 8.3.2 VITAMIN E 60
    • 8.3.3 VITAMIN A 60
    • 8.3.4 VITAMIN K 60
    • 8.3.5 OTHERS 60

9 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS 61

  • 9.1 OVERVIEW 62
  • 9.2 PANCREATIC FUNCTION TEST 64
    • 9.2.1 STOOL 65
      • 9.2.1.1 FECAL ELASTASE TEST 66
      • 9.2.1.2 FECAL FAT TEST 66
    • 9.2.2 SECRETIN PANCREATIC FUNCTION TEST 66
    • 9.2.3 BLOOD TESTS 66
    • 9.2.4 C-MIXED TRIGLYCERIDES BREATH TEST 66
    • 9.2.5 FASTING PLASMA GLUCOSE TEST 66
  • 9.3 IMAGING TEST 66
    • 9.3.1 CT SCANNING 68
    • 9.3.2 MAGNETIC RESONANCE IMAGING TESTS (MRI) 68
    • 9.3.3 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY 68
    • 9.3.4 ENDOSCOPIC ULTRA-SONOGRAPHY (EUS) 68
    • 9.3.5 SECRETIN-STIMULATED MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY 68

10 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE 69

  • 10.1 OVERVIEW 70
  • 10.2 BRANDED 72
    • 10.2.1 CREON 73
    • 10.2.2 ZENPEP 74
    • 10.2.3 PANCREAZE 74
    • 10.2.4 NUTRIZYM 74
    • 10.2.5 PANCREASE MT 74
    • 10.2.6 PANCREX 74
    • 10.2.7 COTAZYM 74
    • 10.2.8 ULTERSA 74
    • 10.2.9 VIOKACE 74
    • 10.2.10 PERTZYE 74
    • 10.2.11 OTHERS 75
  • 10.3 GENERIC 75

11 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER 76

  • 11.1 OVERVIEW 77
  • 11.2 HOSPITALS 79
    • 11.2.1 PRIVATE 80
    • 11.2.2 PUBLIC 80
  • 11.3 SPECIALTY CLINICS 80
  • 11.4 DIAGNOSTIC CENTER 81
  • 11.5 HOMECARE 82
  • 11.6 RESEARCH AND ACADEMIC INSTITUTES 83
  • 11.7 OTHERS 84

12 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 85

  • 12.1 OVERVIEW 86
  • 12.2 DIRECT TENDER 88
  • 12.3 RETAIL PHARMACY 89
  • 12.4 THIRD PARTY DISTRIBUTORS 90
  • 12.5 OTHERS 91

13 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION 92

  • 13.1 OVERVIEW 93
  • 13.2 NORTH AMERICA 97
    • 13.2.1 U.S. 101
    • 13.2.2 CANADA 101
    • 13.2.3 MEXICO 101
  • 13.3 EUROPE 102
    • 13.3.1 GERMANY 107
    • 13.3.2 FRANCE 107
    • 13.3.3 U.K. 107
    • 13.3.4 ITALY 107
    • 13.3.5 SPAIN 107
    • 13.3.6 RUSSIA 107
    • 13.3.7 TURKEY 107
    • 13.3.8 BELGIUM 107
    • 13.3.9 DENMARK 107
    • 13.3.10 NETHERLANDS 108
    • 13.3.11 SWITZERLAND 108
    • 13.3.12 SWEDEN 108
    • 13.3.13 POLAND 108
    • 13.3.14 NORWAY 108
    • 13.3.15 FINLAND 108
    • 13.3.16 REST OF EUROPE 108
  • 13.4 ASIA PACIFIC 109
    • 13.4.1 JAPAN 113
    • 13.4.2 CHINA 113
    • 13.4.3 SOUTH KOREA 113
    • 13.4.4 INDIA 113
    • 13.4.5 AUSTRALIA 113
    • 13.4.6 NEW ZEALAND 113
    • 13.4.7 SINGAPORE 113
    • 13.4.8 THAILAND 113
    • 13.4.9 MALAYSIA 113
    • 13.4.10 VIETNAM 114
    • 13.4.11 TAIWAN 114
    • 13.4.12 INDONESIA 114
    • 13.4.13 PHILIPPINES 114
    • 13.4.14 REST OF ASIA-PACIFIC 114
  • 13.5 SOUTH AMERICA 115
    • 13.5.1 BRAZIL 119
    • 13.5.2 ARGENTINA 119
    • 13.5.3 REST OF SOUTH AMERICA 119
  • 13.6 MIDDLE EAST AND AFRICA 120
    • 13.6.1 SOUTH AFRICA 124
    • 13.6.2 SAUDI ARABIA 124
    • 13.6.3 BAHRAIN 124
    • 13.6.4 U.A.E. 124
    • 13.6.5 KUWAIT 124
    • 13.6.6 OMAN 124
    • 13.6.7 QATAR 124
    • 13.6.8 EGYPT 124
    • 13.6.9 ISRAEL 124
    • 13.6.10 REST OF MIDDLE EAST AND AFRICA 125

14 GLOBAL EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY LANDSCAPE 126

  • 14.1 COMPANY SHARE ANALYSIS: GLOBAL 126
  • 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 127
  • 14.3 COMPANY SHARE ANALYSIS: EUROPE 128
  • 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 129

15 SWOT ANALYSIS 130

16 COMPANY PROFILE 131

  • 16.1 ABBVIE INC. 131
    • 16.1.1 COMPANY SNAPSHOT 131
    • 16.1.2 REVENUE ANALYSIS 131
    • 16.1.3 COMPANY SHARE ANALYSIS 132
    • 16.1.4 PRODUCT PORTFOLIO 132
    • 16.1.5 RECENT DEVELOPMENT 132
  • 16.2 ABBOTT 133
    • 16.2.1 COMPANY SNAPSHOT 133
    • 16.2.2 REVENUE ANALYSIS 133
    • 16.2.3 COMPANY SHARE ANALYSIS 134
    • 16.2.4 PRODUCT PORTFOLIO 134
    • 16.2.5 RECENT DEVELOPMENT 134
  • 16.3 NESTLE 135
    • 16.3.1 COMPANY SNAPSHOT 135
    • 16.3.2 REVENUE ANALYSIS 135
    • 16.3.3 COMPANY SHARE ANALYSIS 136
    • 16.3.4 PRODUCT PORTFOLIO 136
    • 16.3.5 RECENT DEVELOPMENTS 136
  • 16.4 LABORATORY CORPORATION OF AMERICA HOLDINGS (2022) 137
    • 16.4.1 COMPANY SNAPSHOT 137
    • 16.4.2 REVENUE ANALYSIS 137
    • 16.4.3 COMPANY SHARE ANALYSIS 138
    • 16.4.4 PRODUCT PORTFOLIO 138
    • 16.4.5 RECENT DEVELOPMENT 138
  • 16.5 JANSSEN GLOBAL SERVICES, LLC 139
    • 16.5.1 COMPANY SNAPSHOT 139
    • 16.5.2 REVENUE ANALYSIS 139
    • 16.5.3 COMPANY SHARE ANALYSIS 140
    • 16.5.4 PRODUCT PORTFOLIO 140
    • 16.5.5 RECENT DEVELOPMENT 140
  • 16.6 ALCRESTA THERAPEUTICS, INC. 141
    • 16.6.1 COMPANY SNAPSHOT 141
    • 16.6.2 COMPANY SHARE ANALYSIS 141
    • 16.6.3 PRODUCT PORTFOLIO 142
    • 16.6.4 RECENT DEVELOPMENT 142
  • 16.7 BIOSERV DIAGNOSTICS GMBH 143
    • 16.7.1 COMPANY SNAPSHOT 143
    • 16.7.2 PRODUCT PORTFOLIO 143
    • 16.7.3 RECENT DEVELOPMENT 143
  • 16.8 CILIAN AG 144
    • 16.8.1 COMPANY SNAPSHOT 144
    • 16.8.2 PRODUCT PORTFOLIO 144
    • 16.8.3 RECENT DEVELOPMENT 144
  • 16.9 CHIRHOCLIN 145
    • 16.9.1 COMPANY SNAPSHOT 145
    • 16.9.2 COMPANY SHARE ANALYSIS 145
    • 16.9.3 PRODUCT PORTFOLIO 146
    • 16.9.4 RECENT DEVELOPMENT 146
  • 16.10 DIGESTIVE CARE, INC. 147
    • 16.10.1 COMPANY SNAPSHOT 147
    • 16.10.2 PRODUCT PORTFOLIO 147
    • 16.10.3 RECENT DEVELOPMENT 147
  • 16.11 EAGLEBIO 148
    • 16.11.1 COMPANY SNAPSHOT 148
    • 16.11.2 PRODUCT PORTFOLIO 148
    • 16.11.3 RECENT DEVELOPMENT 148
  • 16.12 METAGENICS LLC 149
    • 16.12.1 COMPANY SNAPSHOT 149
    • 16.12.2 PRODUCT PORTFOLIO 149
    • 16.12.3 RECENT DEVELOPMENT 149
  • 16.13 NORDMARK 150
    • 16.13.1 COMPANY SNAPSHOT 150
    • 16.13.2 COMPANY SHARE ANALYSIS 150
    • 16.13.3 PRODUCT PORTFOLIO 151
    • 16.13.4 RECENT DEVELOPMENT 151
  • 16.14 ORGANON GROUP OF COMPANIES. 152
    • 16.14.1 COMPANY SNAPSHOT 152
    • 16.14.2 REVENUE ANALYSIS 152
    • 16.14.3 PRODUCT PORTFOLIO 153
    • 16.14.4 RECENT DEVELOPMENT 153
  • 16.15 SCHEBO BIOTECH AG 154
    • 16.15.1 COMPANY SNAPSHOT 154
    • 16.15.2 PRODUCT PORTFOLIO 154
    • 16.15.3 RECENT DEVELOPMENT 154
  • 16.16 VIVUS LLC 155
    • 16.16.1 COMPANY SNAPSHOT 155
    • 16.16.2 COMPANY SHARE ANALYSIS 155
    • 16.16.3 PRODUCT PORTFOLIO 156
    • 16.16.4 RECENT DEVELOPMENT 156

17 QUESTIONNAIRE 157

18 RELATED REPORTS 160